The U.K. price deal

Britain's pharmaceutical industry is putting its best face on a 7% cut in the price of drugs sold to the National Health System, as a result of pricing negotiations that are held every five years in the U.K. The argument is that the scheme provides secure conditions for five years, along with incentives for R&D.

The last Pharmaceutical Price Regulation Scheme

Read the full 604 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE